Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.08
NAS:AMGN's Cash to Debt is ranked lower than
79% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:AMGN: 1.08 )
Ranked among companies with meaningful Cash to Debt only.
NAS:AMGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 1.03 Max: 8.25
Current: 1.08
0.32
8.25
Equity to Asset 0.39
NAS:AMGN's Equity to Asset is ranked lower than
78% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AMGN: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
NAS:AMGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.56 Max: 0.84
Current: 0.39
0.33
0.84
Interest Coverage 13.36
NAS:AMGN's Interest Coverage is ranked lower than
84% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AMGN: 13.36 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 5.3  Med: 8.46 Max: 29.77
Current: 13.36
5.3
29.77
F-Score: 8
Z-Score: 2.58
M-Score: -2.52
WACC vs ROIC
11.21%
28.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 41.41
NAS:AMGN's Operating margin (%) is ranked higher than
95% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:AMGN: 41.41 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:AMGN' s Operating margin (%) Range Over the Past 10 Years
Min: 26.91  Med: 31.86 Max: 41.41
Current: 41.41
26.91
41.41
Net-margin (%) 33.63
NAS:AMGN's Net-margin (%) is ranked higher than
93% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:AMGN: 33.63 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:AMGN' s Net-margin (%) Range Over the Past 10 Years
Min: 20.68  Med: 26.36 Max: 33.63
Current: 33.63
20.68
33.63
ROE (%) 26.05
NAS:AMGN's ROE (%) is ranked higher than
95% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:AMGN: 26.05 )
Ranked among companies with meaningful ROE (%) only.
NAS:AMGN' s ROE (%) Range Over the Past 10 Years
Min: 14.97  Med: 21.29 Max: 26.05
Current: 26.05
14.97
26.05
ROA (%) 10.20
NAS:AMGN's ROA (%) is ranked higher than
91% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:AMGN: 10.20 )
Ranked among companies with meaningful ROA (%) only.
NAS:AMGN' s ROA (%) Range Over the Past 10 Years
Min: 7.63  Med: 9.3 Max: 12.11
Current: 10.2
7.63
12.11
ROC (Joel Greenblatt) (%) 153.95
NAS:AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:AMGN: 153.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:AMGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 61.87  Med: 79.34 Max: 153.95
Current: 153.95
61.87
153.95
Revenue Growth (3Y)(%) 8.80
NAS:AMGN's Revenue Growth (3Y)(%) is ranked higher than
59% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:AMGN: 8.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:AMGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.8  Med: 15.1 Max: 29.2
Current: 8.8
5.8
29.2
EBITDA Growth (3Y)(%) 19.90
NAS:AMGN's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:AMGN: 19.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:AMGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.6  Med: 15.7 Max: 25.2
Current: 19.9
-1.6
25.2
EPS Growth (3Y)(%) 18.00
NAS:AMGN's EPS Growth (3Y)(%) is ranked higher than
74% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:AMGN: 18.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:AMGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.3  Med: 17.2 Max: 22.1
Current: 18
2.3
22.1
» NAS:AMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

AMGN Guru Trades in Q4 2015

Louis Moore Bacon 125,000 sh (New)
Pioneer Investments 193,844 sh (+222.48%)
George Soros 4,400 sh (+109.52%)
First Eagle Investment 957,656 sh (+73.61%)
Paul Tudor Jones 8,029 sh (+18.07%)
David Carlson 490,000 sh (+4.26%)
Ken Fisher 136,400 sh (+2.07%)
PRIMECAP Management 29,177,226 sh (unchged)
Ruane Cunniff 2,017 sh (unchged)
Lee Ainslie 1,680 sh (unchged)
Samuel Isaly 396,000 sh (unchged)
Ray Dalio Sold Out
John Burbank Sold Out
Andreas Halvorsen Sold Out
John Buckingham 58,522 sh (-0.56%)
Mairs and Power 11,091 sh (-0.67%)
Vanguard Health Care Fund 5,398,985 sh (-3.25%)
Mario Gabelli 39,175 sh (-3.39%)
Dodge & Cox 46,644 sh (-3.52%)
Daniel Loeb 9,042,900 sh (-8.19%)
RS Investment Management 3,758 sh (-8.27%)
Joel Greenblatt 276,751 sh (-31.85%)
First Pacific Advisors 35,640 sh (-33.08%)
Jeremy Grantham 355,863 sh (-38.58%)
Jim Simons 146,500 sh (-90.64%)
John Hussman 900 sh (-97.75%)
» More
Q1 2016

AMGN Guru Trades in Q1 2016

Jim Simons 481,200 sh (+228.46%)
Lee Ainslie 3,460 sh (+105.95%)
First Eagle Investment 1,235,154 sh (+28.98%)
Joel Greenblatt 323,405 sh (+16.86%)
David Carlson 500,000 sh (+2.04%)
PRIMECAP Management 29,181,826 sh (+0.02%)
RS Investment Management 3,758 sh (unchged)
John Hussman 900 sh (unchged)
Louis Moore Bacon Sold Out
First Pacific Advisors Sold Out
George Soros Sold Out
Ruane Cunniff Sold Out
Vanguard Health Care Fund 5,241,755 sh (-2.91%)
John Buckingham 56,652 sh (-3.20%)
Mario Gabelli 37,210 sh (-5.02%)
Dodge & Cox 43,557 sh (-6.62%)
Mairs and Power 9,916 sh (-10.59%)
Ken Fisher 112,693 sh (-17.38%)
Pioneer Investments 157,866 sh (-18.56%)
Paul Tudor Jones 5,300 sh (-33.99%)
Jeremy Grantham 154,015 sh (-56.72%)
Daniel Loeb 3,000,000 sh (-66.82%)
Samuel Isaly 303,000 sh (-23.48%)
» More
Q2 2016

AMGN Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 69,758 sh (New)
Ray Dalio 38,300 sh (New)
Third Avenue Management 135,642 sh (New)
Keeley Asset Management Corp 1,325 sh (New)
Jim Simons 1,176,445 sh (+144.48%)
Joel Greenblatt 485,933 sh (+50.26%)
Lee Ainslie 3,940 sh (+13.87%)
Paul Tudor Jones 5,669 sh (+6.96%)
Samuel Isaly 402,800 sh (+32.94%)
John Hussman 900 sh (unchged)
RS Investment Management 3,758 sh (unchged)
Mairs and Power 9,916 sh (unchged)
Daniel Loeb Sold Out
John Buckingham 56,382 sh (-0.48%)
Vanguard Health Care Fund 5,190,355 sh (-0.98%)
PRIMECAP Management 28,634,341 sh (-1.88%)
Mario Gabelli 36,325 sh (-2.38%)
Dodge & Cox 41,257 sh (-5.28%)
David Carlson 460,000 sh (-8.00%)
Ken Fisher 101,573 sh (-9.87%)
Pioneer Investments 125,883 sh (-20.26%)
First Eagle Investment 936,565 sh (-24.17%)
Jeremy Grantham 2,799 sh (-98.18%)
» More
Q3 2016

AMGN Guru Trades in Q3 2016

Richard Pzena 1,196 sh (New)
George Soros 3,506 sh (New)
Paul Tudor Jones 21,333 sh (+276.31%)
Jim Simons 1,896,341 sh (+61.19%)
Ken Fisher 102,794 sh (+1.20%)
John Hussman 900 sh (unchged)
David Carlson 460,000 sh (unchged)
Keeley Asset Management Corp 1,325 sh (unchged)
Mairs and Power 9,916 sh (unchged)
Ray Dalio Sold Out
Samuel Isaly Sold Out
Third Avenue Management 134,226 sh (-1.04%)
John Buckingham 55,692 sh (-1.22%)
Manning & Napier Advisors, Inc 68,495 sh (-1.81%)
Dodge & Cox 40,157 sh (-2.67%)
PRIMECAP Management 26,560,551 sh (-7.24%)
Lee Ainslie 3,630 sh (-7.87%)
Jeremy Grantham 2,399 sh (-14.29%)
Mario Gabelli 22,425 sh (-38.27%)
Joel Greenblatt 269,204 sh (-44.60%)
Vanguard Health Care Fund 2,759,552 sh (-46.83%)
First Eagle Investment 369,976 sh (-60.50%)
Pioneer Investments 1,554 sh (-98.77%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:GILD, NAS:CELG, OTCPK:NONOF, NAS:BIIB, OTCPK:SHPGF, NAS:REGN, OTCPK:CSLLY, NAS:ALXN, OTCPK:RHHBY, NAS:VRTX, NAS:INCY, OTCPK:ALIOY, NAS:BMRN, OTCPK:GIKLY, NAS:MDVN, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:ALKS » details
Traded in other countries:AMGN.Argentina, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.

Amgen Inc was incorporated in the State of Delaware on October 31, 1986. It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics. Its Cardiovascular products include Repatha, Corlanor, Inflammation products include Brodalumab, Nephrology, Oncology products include BLINCYTO, Kyprolis, Neulasta, Rilotumumab, Talimogene laherparepvec, Trebananib, Biosimilars, among others. Its geographic areas of operations include USA, Europe and Canada. Certain raw materials, medical devices and components necessary for the commercial and/or clinical manufacturing of the Company's products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be its only sources for such materials. The Company's sales and marketing forces are mainly located in the United States and Europe. Together with its partners, the Company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In the United States, the Company sells to pharmaceutical wholesale distributors. The Company's competitors include Teva Pharmaceutical Industries Ltd., Janssen Biotech, Inc., AbbVie Inc., Merck & Company, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly/Bristol-Myers Squibb Company, Merck KGaA, Genentech, Inc., GlaxoSmithKline PLC, Millennium Pharmaceuticals, Inc., and Celgene Corporation. Some of the Company's patents include Neulasta, NEUPOGEN, Enbrel, XGEVA, Prolia, EPOGEN, Aranesp, Sensipar, Mimpara, Kyprolis, Nplate, Vectibix, and BLINCYTO. The Company's business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 14.26
AMGN's P/E(ttm) is ranked higher than
78% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. AMGN: 14.26 )
Ranked among companies with meaningful P/E(ttm) only.
AMGN' s P/E(ttm) Range Over the Past 10 Years
Min: 10.4  Med: 16.6 Max: 30.95
Current: 14.26
10.4
30.95
Forward P/E 11.83
AMGN's Forward P/E is ranked higher than
73% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. AMGN: 11.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.26
AMGN's PE(NRI) is ranked higher than
79% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. AMGN: 14.26 )
Ranked among companies with meaningful PE(NRI) only.
AMGN' s PE(NRI) Range Over the Past 10 Years
Min: 10.4  Med: 16.6 Max: 30.95
Current: 14.26
10.4
30.95
Price/Owner Earnings (ttm) 13.29
AMGN's Price/Owner Earnings (ttm) is ranked higher than
74% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. AMGN: 13.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AMGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.72  Med: 13.98 Max: 29.05
Current: 13.29
9.72
29.05
P/B 3.47
AMGN's P/B is ranked higher than
50% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. AMGN: 3.47 )
Ranked among companies with meaningful P/B only.
AMGN' s P/B Range Over the Past 10 Years
Min: 1.8  Med: 3.53 Max: 5.21
Current: 3.47
1.8
5.21
P/S 4.77
AMGN's P/S is ranked higher than
71% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. AMGN: 4.77 )
Ranked among companies with meaningful P/S only.
AMGN' s P/S Range Over the Past 10 Years
Min: 3.03  Med: 4.36 Max: 8.2
Current: 4.77
3.03
8.2
PFCF 13.70
AMGN's PFCF is ranked higher than
72% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. AMGN: 13.70 )
Ranked among companies with meaningful PFCF only.
AMGN' s PFCF Range Over the Past 10 Years
Min: 8.85  Med: 13.58 Max: 25.2
Current: 13.7
8.85
25.2
POCF 12.49
AMGN's POCF is ranked higher than
73% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. AMGN: 12.49 )
Ranked among companies with meaningful POCF only.
AMGN' s POCF Range Over the Past 10 Years
Min: 7.3  Med: 12.08 Max: 20.75
Current: 12.49
7.3
20.75
EV-to-EBIT 10.25
AMGN's EV-to-EBIT is ranked higher than
69% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. AMGN: 10.25 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 13.1 Max: 22.6
Current: 10.25
7.4
22.6
EV-to-EBITDA 8.52
AMGN's EV-to-EBITDA is ranked higher than
72% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. AMGN: 8.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 10.6 Max: 18.2
Current: 8.52
6.2
18.2
PEG 0.82
AMGN's PEG is ranked higher than
75% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. AMGN: 0.82 )
Ranked among companies with meaningful PEG only.
AMGN' s PEG Range Over the Past 10 Years
Min: 0.18  Med: 1.04 Max: 3.05
Current: 0.82
0.18
3.05
Shiller P/E 24.04
AMGN's Shiller P/E is ranked higher than
74% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. AMGN: 24.04 )
Ranked among companies with meaningful Shiller P/E only.
AMGN' s Shiller P/E Range Over the Past 10 Years
Min: 17.3  Med: 26.83 Max: 54.6
Current: 24.04
17.3
54.6
Current Ratio 4.35
AMGN's Current Ratio is ranked higher than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. AMGN: 4.35 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.43 Max: 6.33
Current: 4.35
1.31
6.33
Quick Ratio 4.09
AMGN's Quick Ratio is ranked higher than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. AMGN: 4.09 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 3.03 Max: 5.75
Current: 4.09
1.17
5.75
Days Inventory 225.87
AMGN's Days Inventory is ranked lower than
75% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. AMGN: 225.87 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 225.87
219.41
374.86
Days Sales Outstanding 51.54
AMGN's Days Sales Outstanding is ranked higher than
59% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. AMGN: 51.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.64 Max: 67.84
Current: 51.54
46.32
67.84
Days Payable 72.28
AMGN's Days Payable is ranked higher than
60% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. AMGN: 72.28 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 86.19 Max: 117.72
Current: 72.28
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.83
AMGN's Dividend Yield is ranked higher than
74% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 1.46 vs. AMGN: 2.83 )
Ranked among companies with meaningful Dividend Yield only.
AMGN' s Dividend Yield Range Over the Past 10 Years
Min: 0.48  Med: 1.65 Max: 2.86
Current: 2.83
0.48
2.86
Dividend Payout 0.38
AMGN's Dividend Payout is ranked higher than
56% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. AMGN: 0.38 )
Ranked among companies with meaningful Dividend Payout only.
AMGN' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.35 Max: 0.56
Current: 0.38
0.22
0.56
Dividend Growth (3y) 29.90
AMGN's Dividend Growth (3y) is ranked higher than
86% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. AMGN: 29.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AMGN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 63.3
Current: 29.9
0
63.3
Forward Dividend Yield 2.76
AMGN's Forward Dividend Yield is ranked higher than
75% of the 231 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. AMGN: 2.76 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.83
AMGN's Yield on cost (5-Year) is ranked higher than
83% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 1.66 vs. AMGN: 2.83 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AMGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.48  Med: 1.65 Max: 2.86
Current: 2.83
0.48
2.86
3-Year Average Share Buyback Ratio 0.10
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. AMGN: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.2  Med: 1.7 Max: 8.7
Current: 0.1
-8.2
8.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.91
AMGN's Price/Tangible Book is ranked lower than
91% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. AMGN: 19.91 )
Ranked among companies with meaningful Price/Tangible Book only.
AMGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.67  Med: 14.08 Max: 150.81
Current: 19.91
4.67
150.81
Price/Projected FCF 0.86
AMGN's Price/Projected FCF is ranked higher than
87% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. AMGN: 0.86 )
Ranked among companies with meaningful Price/Projected FCF only.
AMGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.13 Max: 6.23
Current: 0.86
0.59
6.23
Price/DCF (Earnings Based) 0.82
AMGN's Price/DCF (Earnings Based) is ranked higher than
65% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. AMGN: 0.82 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.09
AMGN's Price/Median PS Value is ranked lower than
61% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. AMGN: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
AMGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.72  Med: 1.38 Max: 5.15
Current: 1.09
0.72
5.15
Price/Peter Lynch Fair Value 0.62
AMGN's Price/Peter Lynch Fair Value is ranked higher than
87% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. AMGN: 0.62 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMGN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.35 Max: 3.34
Current: 0.62
0.58
3.34
Price/Graham Number 3.53
AMGN's Price/Graham Number is ranked lower than
64% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. AMGN: 3.53 )
Ranked among companies with meaningful Price/Graham Number only.
AMGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.52  Med: 4.18 Max: 11.67
Current: 3.53
1.52
11.67
Earnings Yield (Greenblatt) (%) 9.79
AMGN's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. AMGN: 9.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.4  Med: 7.7 Max: 13.6
Current: 9.79
4.4
13.6
Forward Rate of Return (Yacktman) (%) 28.73
AMGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. AMGN: 28.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.2  Med: 18.7 Max: 95.7
Current: 28.73
2.2
95.7

More Statistics

Revenue (TTM) (Mil) $22,562
EPS (TTM) $ 10.01
Beta1.49
Short Percentage of Float1.18%
52-Week Range $133.64 - 176.85
Shares Outstanding (Mil)743.92

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 22,716 23,291 22,402 21,269
EPS ($) 11.39 12.20 12.20 11.10
EPS w/o NRI ($) 11.39 12.20 12.20 11.10
EPS Growth Rate
(3Y to 5Y Estimate)
1.72%
Dividends Per Share ($) 3.97 4.77
» More Articles for NAS:AMGN

Headlines

Articles On GuruFocus.com
6 Worthy Dividend Stocks Down 10% or More Nov 22 2016 
AbbVie Reports 3rd Quarter Results Nov 01 2016 
Martin Whitman's Top Recent Investments Oct 12 2016 
FDA Approval of Amjevita Need Not Worry AbbVie Shareholders Sep 28 2016 
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 
Third Avenue Fund Comments on Amgen Sep 14 2016 
Third Avenue Fund Comments on Amgen Sep 14 2016 
Third Avenue Value Fund 3rd Quarter Letter Sep 14 2016 
Lee Ainslie Invests in Apple, American Airlines Sep 12 2016 
AbbVie: Investors Apprehensive About Humira Sep 06 2016 

More From Other Websites
A broad rally drives Dow, S&P 500 indexes to record highs Dec 07 2016
Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point Dec 07 2016
4 Stocks Set for Dividend Hikes Next Week Dec 07 2016
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus Dec 07 2016
Rivals Kite Pharma, Juno Therapeutics Tank On Cancer Data; Spark Flies Dec 06 2016
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell Dec 05 2016
Amgen Rolls Out Kidney Disease Campaign (AMGN) Dec 05 2016
Amgen/Allergan File for EU Approval of Avastin Biosimilar Dec 05 2016
Amgen, Allergan File for Avastin Biosimilar in EU (AGN) Dec 05 2016
Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment Dec 04 2016
Here's How Much Trump Tax Cuts Could Boost The Stock Market Dec 02 2016
Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech Dec 02 2016
Amgen Announces Launch Of Blood Counts™ And Collaboration With StoryCorps To Record And Share... Dec 02 2016
Allergan & Amgen Looking for Approvals (AGN, AMGN) Dec 02 2016
Amgen, Allergan apply for European nod for Avastin biosimilar Dec 02 2016
Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines... Dec 02 2016
Bluebird Rockets On Myeloma Drug; Celgene Gets Boost Dec 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)